# Darolutamide+ADT Post-RP w/o ePLND in hrPC: Briganti 2019

> **NCT07282197** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Peking University First Hospital** · enrollment: 40 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Darolutamide (BAY 1841788)

## Key facts

- **NCT ID:** NCT07282197
- **Lead sponsor:** Peking University First Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01
- **Primary completion:** 2029-03
- **Final completion:** 2029-06
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07282197

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07282197, "Darolutamide+ADT Post-RP w/o ePLND in hrPC: Briganti 2019". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07282197. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*